Sangamo Therapeutics Inc SGMO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if SGMO is a good fit for your portfolio.
News
-
Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
-
Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering
-
Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
-
Sangamo Therapeutics Announces Data From Novel Proprietary Neurotropic AAV Capsid Demonstrating Industry-leading Blood-brain Barrier Penetration and Brain Transduction in NHPs
-
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2023 Conference Call and Webcast
-
Sangamo Therapeutics Announces U.S. FDA Alignment on Abbreviated Pathway to Potential Approval and EMA Prime Eligibility for ST-920 in Fabry Disease
-
Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit and Differentiated Safety Profile
-
Stocks to Watch: Meta, Teradyne, United Rentals, Sangamo Therapeutics
Trading Information
- Previous Close Price
- $0.50
- Day Range
- $0.50–0.53
- 52-Week Range
- $0.29–1.78
- Bid/Ask
- $0.51 / $0.53
- Market Cap
- $107.44 Mil
- Volume/Avg
- 662,649 / 2.5 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.50
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington’s Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 405
- Website
- https://www.sangamo.com
Comparables
Valuation
Metric
|
SGMO
|
NTLA
|
AVIR
|
---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.08 | 1.77 | 0.56 |
Price/Sales | 0.50 | 48.99 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
SGMO
NTLA
AVIR
Financial Strength
Metric
|
SGMO
|
NTLA
|
AVIR
|
---|---|---|---|
Quick Ratio | 1.72 | 8.23 | 17.86 |
Current Ratio | 1.98 | 8.67 | 18.24 |
Interest Coverage | — | — | — |
Quick Ratio
SGMO
NTLA
AVIR
Profitability
Metric
|
SGMO
|
NTLA
|
AVIR
|
---|---|---|---|
Return on Assets (Normalized) | −22.55% | −25.49% | −15.46% |
Return on Equity (Normalized) | −35.70% | −30.88% | −16.16% |
Return on Invested Capital (Normalized) | −34.64% | −31.84% | −19.92% |
Return on Assets
SGMO
NTLA
AVIR
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Fzswstbgs | Qmcmr | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Tdhbjcn | Xhxkzg | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Gcgdkyt | Fjqgsv | $97.8 Bil | |
MRNA
| Moderna Inc | Nmrnfkjnk | Btz | $38.8 Bil | |
ARGX
| argenx SE ADR | Cpcrrkjf | Ycmn | $22.0 Bil | |
BNTX
| BioNTech SE ADR | Fzrfmbm | Cmcd | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Qcvgvfcld | Vhfpzx | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Llldsxrw | Fmhfhy | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Bhtjsvpbd | Lfyzqrz | $12.5 Bil | |
INCY
| Incyte Corp | Bnjnccnr | Zyspy | $11.5 Bil |